Stockscreener 앱 받기
83.18
0.10%
-0.08
Merck Co Inc 주식(MRK)의 최신 뉴스
Merck & Co., Inc. SEC 10-Q Report - TradingView
Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology - insights.citeline.com
Liver Cancer Treatment Market is expected to generate a revenue of USD 8.88 Billion by 2031, Globally, at 13.45% CAGR: Verified Market Research® - GlobeNewswire Inc.
Merck & Co., Inc. (MRK): Jim Cramer Agrees – “Merck’s A Good Company” - Insider Monkey
Jim Cramer Says He Likes Bristol-Myers Squibb (BMY) More Than Merck Due to Schizophrenia Drug - Yahoo Finance
Arvinas, Entrada cut staff; Merck builds US hub for Keytruda - BioPharma Dive
June 13th Options Now Available For Merck (MRK) - Nasdaq
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know - Yahoo Finance
AmacaThera and Merck Animal Health Announce Collaboration in Animal Health - PR Newswire
Pharmaceutical company Merck to invest $1 billion in Delaware plant - The American Bazaar
Is Merck & Co. Inc. (MRK) the Best Dow Stock for the Next 12 Months? - Yahoo Finance
In Brief: Merck To Invest $1bn In New US Biologics Production - insights.citeline.com
Merck & Co courts Washington with Delaware build statement - The Pharma Letter
Merck Shareholder Drops Suit Against Execs Over Gardasil Demand - Bloomberg Law News
Merck & Co., Inc. (MRK): Among Billionaire Cliff Asness’ Stock Picks with Huge Upside Potential - Insider Monkey
Guggenheim Adjusts Merck & Co.'s Price Target to $108 From $115 - marketscreener.com
Guggenheim cuts Merck stock target to $108, keeps Buy rating By Investing.com - Investing.com India
Merck (MRK) Price Target Reduced by Guggenheim Analyst | MRK Sto - GuruFocus
Merck & Co. (MRK) Looks to New Cholesterol Drug as Keytruda Expiration Looms - TipRanks
Analysis of Cancer Immunotherapy Technologies and Global Markets to 2029 - GlobeNewswire Inc.
Merck plans to move manufacturing of its biggest drug, Keytruda, to a new US factory and lab in Delaware - The Daily Gazette
Merck breaks ground at Chestnut Run - WDEL.com
How To Put $100 In Your Retirement Fund Each Month With Merck Stock - Benzinga
Merck to invest $1 billion in new Delaware plant to boost US manufacturing - Reuters
Merck plans to bring Keytruda production to the US with $1B biologics factory - Endpoints News
Is Merck & Co., Inc. (MRK) the Worst-Performing Blue Chip Stock So Far in 2025? - Insider Monkey
Merck to build $1B biologics center in Wilmington - The Business Journals
Merck Begins Construction of $1 Billion Biologics Facility in Delaware - marketscreener.com
Merck to invest $1 billion in U.S. drug manufacturing plant - CBS News
Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware | MRK Stock News - GuruFocus
Merck (MRK) to Invest $1 Billion in Delaware Manufacturing Plant - GuruFocus
Merck Breaks Ground On New $1 Billion Biologics Center Of Excellence In Wilmington, Delaware - marketscreener.com
Merck (MRK) Commences Construction on Advanced Biologics Facilit - GuruFocus
Merck to build $1B Delaware plant to ensure domestic supply of Keytruda (MRK:NYSE) - Seeking Alpha
Stock Watch: Sanofi, Merck Open Windows Into Geopolitical Risks - insights.citeline.com
Merck to invest $1 billion in new US site - breakingthenews.net
Merck to invest $1 billion in new Delaware plant to boost US manufacturing, WSJ reports - marketscreener.com
Merck To Spend $1 Billion On New Factory To Make U.S. Supplies Of Cancer Drug Keytruda- WSJ - marketscreener.com
Exclusive | Merck to Spend $1 Billion on New Factory to Make U.S. Supplies of Blockbuster Drug - WSJ
Merck Set To Add Perioperative Head-And-Neck Cancer To Keytruda Label - insights.citeline.com
Merck & Co. CMO Eliav Barr Assures On Pipeline As Keytruda LOE Looms Large - insights.citeline.com
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion - Benzinga
Jim Cramer Says Merck & Co (MRK) Has ‘Turned Into a Complete Nightmare’ - Insider Monkey
Shock value: Merck’s $3.9B Springworks grab provides jolt - BioWorld MedTech
Is Merck & Co., Inc. (MRK) the Most Profitable Blue Chip Stock to Buy Now? - Insider Monkey
HSBC Adjusts Merck & Co Price Target to $100 From $115, Maintains Buy Rating - marketscreener.com
Earnings Update: Merck & Co., Inc. (NYSE:MRK) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - GlobeNewswire Inc.
Germany’s Merck Set to Buy SpringWorks in $3.9 Billion Deal - WSJ
Merck KGaA strikes $3.9bn deal for SpringWorks - Pharmaceutical Technology
Merck: positive results in head & neck cancer - marketscreener.com
Merck's Keytruda Improves Head and Neck Cancer Survival by 34% in Study - marketscreener.com
Merck & Co., Inc. (MRK): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential - Insider Monkey
Merck & Co., Inc. (NYSE:MRK) Rating Lowered to “Buy” at StockNews.com - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Merck Stays Confident On M&A Despite Market Uncertainty: AnalystMerck & Co (NYSE:MRK) - Benzinga
Merck stock gains on Summit data for cancer drug (MRK:NYSE) - Seeking Alpha
BMO Capital Adjusts Price Target on Merck to $82 From $89 - marketscreener.com
Goldman Sachs Adjusts Merck Price Target to $99 From $103, Maintains Buy Rating - marketscreener.com
Germany's Merck says in late-stage discussions to buy SpringWorks for $3.5 billion - Reuters
Morgan Stanley Cuts Price Target on Merck to $99 From $106, Keeps Equalweight Rating - marketscreener.com
Halozyme files lawsuit against Merck over SC Keytruda - The Pharma Letter
Merck & Co Inc (MRK) Q1 2025 Earnings: GAAP EPS of $2.01 and Rev - GuruFocus
2.66%
0.90%
자본화:
|
볼륨(24시간):